Overview
Prospective, multicenter, open label, randomized controlled clinical trial to compare the effects of an early catheter-directed treatment plus conventional care with conventional care in patients with high-risk pulmonary embolism
Eligibility
Inclusion Criteria:
- Pulmonary embolism as confirmed by CT angiogram with high mortality risk as defined
by ESC guidelines:
- One of the following: i. Cardiac arrest or ii. obstructive shock (systolic BP <90 mmHg or vasopressors required to achieve a BP ≥90 mmHg despite an adequate filling status), in combination with end-organ hypoperfusion (cold, clammy skin, oliguria or serum lactate ≥2 mmol/L) and b) Signs of right-ventricular dysfunction on transthoracic echocardiogram or CT scan
- Age ≥18 years
Exclusion Criteria:
- Contraindications for catheter-based treatment
- Contraindications to systemic fibrinolytic treatment or anticoagulation*
- Active, potentially life-threatening bleeding
- Surgery within 24h before screening
- Cranial or spinal surgery within 14d before screening
- Stroke within 14d before screening
- Intracranial tumor
- Any condition not listed here but estimated as clinically relevant as judged by the treating investigator
- Pregnancy
- Patients with contraindications to systemic fibrinolysis or anticoagulation can be enrolled in a third study arm (registry) and undergo catheter-directed therapy.